JetBlue Airways (NASDAQ:JBLU) shares slid more than 10% Tuesday after CEO Robin Hayes announced that he will resign in February and analysts at Bank of America hit the company with a downgrade.
Hayes will be succeeded by Joanna Geraghty, JetBlue’s president and a 20-year employee of the airline, starting on February 12. Geraghty will become the first woman to be CEO of a major US airline.
United Airlines Holdings Inc (NASDAQ:UAL) having 79 Boeing 737 Max 9 planes grounded by the FAA hasn’t bothered Bank of America analysts.
The firm hit United with a double upgrade to Buy from Underperform and raised its price target to $56 from $40. Shares of the airline rose 2.2% Tuesday afternoon to $43.38.
Medicus Pharma (TSX-V:MDCX), a healthcare-focused holding company, is making strides in the clinical trial stage by acquiring or partnering with life-science firms, analysts at Zacks Research believe.
In a note initiating coverage of the healthcare stock, Zacks analysts noted that the company's first acquisition, SkinJect, offers a patented transdermal patch for basal cell carcinoma (BCC) treatment.
UK banks are facing a much tougher year in 2024 than over the past twelve months, according to analysts at Liberum.
Much of Europe’s outperformance is set to reverse in 2024 as the rate cycle rolls over, loan books contract and weak economic growth test underwriting standards, believes the broker.
British Airways-owner International Consolidated Airlines Group SA (LSE:IAG) should get a boost from an increasingly favourable macroeconomic outlook for the aviation sector.
According to RBC, a dip in airline fuel costs should offer a roughly 2% boost to the operator’s 2024 pre-tax earnings estimates, which the bank forecasts to come in at £3.37 billion.
Shell PLC (LSE:SHEL, NYSE:SHEL) has perked up 0.9% today, after Monday’s fall, with much of the movement dictated by a rally in the oil price.
The price of Brent has rallied around 2.8% to $78.19/barrel after being as much as 4% lower on Monday after the Saudi price cuts.
Premier African Minerals’ latest assay results from drilling at Zulu in Zimbabwe were encouraging, especially the significant assay results from outside of the current mine plan said broker ShoreCap.
A total of 58m was assayed from surface trenches and the best results returned 6.7m grading 1.0% Li2O, 7.5m grading 1.8% Li2O and 5.0m grading 1.8% Li2O.
Even though Legal & General Group PLC (LSE:LGEN) shares rose over 10% in the final few weeks of last year, Deutsche Bank said “we believe there is plenty more to go”.
The bank upped its share price target to 295p to 305p, having upgraded its rating on the life insurer to a 'buy' in late November.
Glencore is the mining giant with the most scope to disappoint on dividends in the coming results season, suggest analysts at UBS.
All of the mining giants have paid out huge sums in recent years but with the prices of bulk commodities under pressure, UBS suggests some of the payments this time might not be so bumper.
The new Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) driver monitoring system (DMS) launched today is significant for the company, say analysts at Stifel, as it provides a feature-rich product at a much lower production cost "and can therefore catalyse revenues in this division".
A 'buy' rating was reiterated along with a share price target of 15p, versus the last closing price in London of 5.32p.
Eden Research PLC (AIM:EDEN, OTCQB:EDNSF)’s regulatory approval of its biofungicide product Mevalone in the state of California amounts to a “significant milestone” for the sustainable agriculture group, according to Cavendish analysts.
This development is particularly notable given California's prominence in wine production, where Mevalone's target disease, botrytis, is a common concern.
Morgan Stanley (NYSE:MS) has highlighted its top picks in the leisure and hotel sectors for 2024, citing Flutter Entertainment PLC (LSE:FLTR), Accor, Whitbread PLC (LSE:WTB) and Compass Group PLC (LSE:CPG) as top 'overweight' stocks with a positive outlook on their future performance.
In the betting space, Paddy Power-owner Flutter’s US listing “should be positive for investor attention, liquidity and comparability”, according to the bank, with the group’s transformative financial profile and M&A opportunities paving the way for shares to outperform.
B&M European Value Retail SA (LSE:BME)’s shorter than usual update on the three months to December might well leave investors asking questions, according to Shore Cap analysts.
Though the FTSE 100-listed retailer unveiled group revenue growth of 5.0% year-on-year for the period on Tuesday, a lack of like-for-like sales information caught the eyes of analysts at the bank.
Marks and Spencer Group PLC (LSE:MKS) was UK fashion’s “standout performer” this festive period, according to research by Barclays.
Experts at the bank have used Kantar’s data to distinguish the rate of overall growth for the sector and found that M&S comfortably outperformed this.
GSK PLC (LSE:GSK, NYSE:GSK) should deliver better than expected fourth-quarter results on January 31, according to Barclays, amid heightened expectations driven by the robust performance of its RSV vaccine, Arexvy.
Analysts at the bank, who also wondered if 2024 could be "the year Zantac goes away?", said the last set of quarterly results were muddied by the performance of Arexvy.
Bioshares has a Speculative Buy Class B recommendation for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) after the company released positive trial results from its Phase Ib study in patients with T-cell lymphomas.
The results surpassed Prescient’s expectations from both safety and early efficacy perspectives, especially in the difficult-to-treat patient population.